TY - JOUR
T1 - Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy
AU - Pascual-Goñi, Elba
AU - Martín-Aguilar, Lorena
AU - Lleixà, Cinta
AU - Martínez-Martínez, Laura
AU - Simón-Talero, Manuel J.
AU - Díaz-Manera, Jordi
AU - Cortés-Vicente, Elena
AU - Rojas-García, Ricard
AU - Moga, Esther
AU - Juárez, Cándido
AU - Illa, Isabel
AU - Querol, Luis
PY - 2019/4/16
Y1 - 2019/4/16
N2 - © 2019, The Author(s). Antibodies against myelin-associated glycoprotein (MAG) almost invariably appear in the context of an IgM monoclonal gammopathy associated neuropathy. Very few cases of anti-MAG neuropathy lacking IgM-monoclonal gammopathy have been reported. We investigated the presence of anti-MAG antibodies in 69 patients fulfilling diagnostic criteria for CIDP. Anti-MAG antibodies were tested by ELISA and confirmed by immunohistochemistry. We identified four (5.8%) anti-MAG positive patients without detectable IgM-monoclonal gammopathy. In two of them, IgM-monoclonal gammopathy was detected at 3 and 4-year follow-up coinciding with an increase in anti-MAG antibodies titers. In conclusion, anti-MAG antibody testing should be considered in chronic demyelinating neuropathies, even if IgM-monoclonal gammopathy is not detectable.
AB - © 2019, The Author(s). Antibodies against myelin-associated glycoprotein (MAG) almost invariably appear in the context of an IgM monoclonal gammopathy associated neuropathy. Very few cases of anti-MAG neuropathy lacking IgM-monoclonal gammopathy have been reported. We investigated the presence of anti-MAG antibodies in 69 patients fulfilling diagnostic criteria for CIDP. Anti-MAG antibodies were tested by ELISA and confirmed by immunohistochemistry. We identified four (5.8%) anti-MAG positive patients without detectable IgM-monoclonal gammopathy. In two of them, IgM-monoclonal gammopathy was detected at 3 and 4-year follow-up coinciding with an increase in anti-MAG antibodies titers. In conclusion, anti-MAG antibody testing should be considered in chronic demyelinating neuropathies, even if IgM-monoclonal gammopathy is not detectable.
KW - EUROPEAN FEDERATION
KW - GLYCOPROTEIN ANTIBODY
KW - GUIDELINE
KW - JOINT TASK-FORCE
KW - MANAGEMENT
KW - NEUROLOGICAL SOCIETIES
KW - PERIPHERAL-NERVE SOCIETY
KW - PLACEBO-CONTROLLED TRIAL
KW - RITUXIMAB
U2 - 10.1038/s41598-019-42545-8
DO - 10.1038/s41598-019-42545-8
M3 - Article
C2 - 30992531
SN - 2045-2322
VL - 9
SP - 6155
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 6155
ER -